descr

PaxVax ready to strike M&A deals that prove its sales model, CEO says

Thursday, January 15, 2015

PaxVax entered the M&A arena last summer, nabbing typhoid vaccine Vivotif from Johnson & Johnson subsidiary Crucell. And it's not stopping there, CEO Ken Kelley says.

The California company has another specialty travel vaccine deal coming that it's currently negotiating, the helmsman told FierceVaccines in an interview at this week's JP Morgan Healthcare Conference. It expects to announce that pact--along with one for a travel med--in the first half of this year.

Pages

Cholera

18.97
-72.29

Anthrax

40.71
-74.01

Typhoid

21.00
78.00

Hepatitis A

39.92
32.83

H5N1, Dengue

& HIV

-0.78
113.92

for protection wherever you are and wherever you go

PaxVax is a fully integrated specialty vaccine company committed to developing and commercializing innovative vaccines against infectious diseases.

PaxVax: Better Vaccines

37.44
-122.14
Subscribe to PaxVax - Socially Responsible Vaccines RSS